Get the Stockscreener App
2.94
2.44%
0.07
After Hours:
2.95
0.01
+0.34%
Hcw Biologics Inc stock is traded at $2.94, with a volume of 35,624.
It is up +2.44% in the last 24 hours and down -18.33% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
See More
Previous Close:
$2.87
Open:
$2.81
24h Volume:
35,624
Relative Volume:
0.26
Market Cap:
$5.40M
Revenue:
$6.59M
Net Income/Loss:
$-18.12M
P/E Ratio:
-0.3108
EPS:
-9.4605
Net Cash Flow:
$-11.45M
1W Performance:
-14.29%
1M Performance:
-18.33%
6M Performance:
-25.38%
1Y Performance:
-89.42%
1-Day Range:
$2.80
$2.97
1-Week Range:
$2.7001
$3.81
52-Week Range:
$1.50
$36.65
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
2.94 | 3.89M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCWB Looks 90.0% Undervalued on GF Value™ - GuruFocus
HCW Biologics Strengthens U.S. Patent Estate for Its Lead - globenewswire.com
HCW Biologics Inc. SEC Filing (Sep 1, 2026) - Stock Titan
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceBackspread Trade - siam.in
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Canada
Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells - Stock Titan
HCW (HCWB) Financial Update: The EPS Result Is Above Expectation in the Latest Reading; Investor Response: The Share Price Adds 2.83% on the DayEarnings Call Transcript - vinanet.vn
HCW (HCWB): Finishes 2.83% Up at $2.18 in the Latest Reading; Range Check: Price Remains Between $2.07 Support and $2.29 ResistanceBPI Bull Confirmed - vinanet.vn
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - Vinanet
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
HCW Biologics (HCWB) posts higher 2026 revenue but flags going-concern risk - Stock Titan
HCW Biologics Reports Second Quarter 2026 Financial Results and Updates HCW9302 Alopecia Areata Program, HCW11-018b Development and Financing Activities - Quiver Quantitative
HCW Biologics trial: 3 alopecia patients cut SALT scores 25%+ - Stock Titan
HCWB Q1 2026 Earnings: Surprise EPS of $2.22 vs. Expected Loss, Yet Shares Slip 3.06%Consensus Miss Rate - Vinanet
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HCWB Q1 2026 Earnings: EPS of $2.22 Surges Past Loss EstimatesEarnings Power Value - vinanet.vn
HCW Biologics (HCWB) completes $1.6M exempt equity and warrant sale - Stock Titan
HCW Biologics | D: Filing D - Moomoo
HCWB Q2'26 Earnings: EPS estimate is (1.98) USD - TradingView
Price to earnings forward of HCW Biologics Inc. – NASDAQ:HCWB - TradingView
HCW Biologics (HCWB) director buys stock, entitled to new warrants - Stock Titan
HCW Biologics Announces $1.6 Million Private Placement Financing - The Globe and Mail
HCWB Q1 2026 Earnings: Surprising Profitability Driven by Non-Operating GainsHigh Growth Earnings - vinanet.vn
HCW Biologics Raises $1.6 Million in Private Placement; Units Priced at $2.585 - TradingView
HCW Biologics Prices $1.6 Million Private Placement Offering - marketscreener.com
HCWB Looks 94.1% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
HCW Biologics prices $1.6M private placement offering By Investing.com - Investing.com Canada
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering - GlobeNewswire
HCW Biologics prices $1.6M private placement with insiders - Investing.com
HCWB|HCW Biologics Inc|Price:2.640|Chg%:+0.140 - TradingKey
HCW Biologics Inc (HCWB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HCW Biologics Inc (HCWB) Cash Flow - TradingKey
HCW Biologics (HCWB) Surges 6% as Shares Test Key Resistance Near $2.78Large Cap Trends - vinanet.vn
HCW Biologics Inc (HCWB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HCW Biologics Inc (HCWB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HCWB Q1 2026 Earnings: Surprise Profitability Amidst No RevenueProfit Growth Outlook - vinanet.vn
TradingKey - TradingKey
HCWB|HCW Biologics Inc|Price:2.500|Chg%:-0.380 - TradingKey
HCWB|HCW Biologics Inc|Price:3.430|Chg%:+0.260 - TradingKey
HCWB Q1 2026 Earnings: Surprise Net Income Amid Pre-Revenue StatusGuidance Downgrade Alert - vinanet.vn
HCW Biologics Inc (HCWB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
HCW Biologics Inc. Revenue Breakdown – NASDAQ:HCWB - TradingView
HCW Biologics Inc. (HCWB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hcw Biologics Inc Stock (HCWB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flowers Lee | SVP of Business Development |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
8,691 |
| GARRETT SCOTT T | Director |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
41,644 |
| Wong Hing C | Chief Executive Officer |
May 22 '26 |
Buy |
1.41 |
113,879 |
160,000 |
615,790 |
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):